CTLA4 and cancer: The majority of biomarkers significant in individual subgroups were the same as those attaining significance in the pan-cancer meta-analysis, with the exception of HLA B44 supertype (Chowell et al., 2018) and germline HLA-I evolutionary divergence (Chowell et al., 2019), which, while not significant overall, were significant in the melanoma anti-CTLA-4 cohorts (OR = 1.65 [1.11–2.46], p = 1.3 × 10−2 and OR = 1.71 [1.07–2.75], p = 2.5 × 10−2, respectively).